Profile: Sierra Oncology Inc (SRRA.OQ)

SRRA.OQ on NASDAQ Stock Exchange Global Market

8:19pm IST
Change (% chg)

$-0.01 (-1.94%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., incorporated on May 8, 2003, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network. SRA737 is being investigated in approximately two Phase I clinical trials in patients with advanced cancer.

Sierra Oncology is also advancing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase (Cdc7) kinase undergoing preclinical development. Sierra is building a range of pipeline of various oncology assets against targets at the edge of cancer biology. The Company’s SRA737 and SRA141 target the DDR network, a scientifically approach with far-reaching potential across oncology. SRA141 is an orally available small molecule inhibitor of Cdc7. Cdc7 is a serine-threonine kinase, which acts as a regulator of both DNA replication and the DDR network. SRA141 interacts with DNA replication and the DDR network in a way to SRA737. Inhibiting both Chk1 and Cdc7 simultaneously may be advantageous and presents the potential for combination strategies for SRA737 and SRA141.

Company Address

Sierra Oncology Inc

2150-885 Georgia St W
P: +1604.5586536
F: +1302.6365454

Company Web Links